Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from ...

The decision was taken following a plenary meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) on May 5, 2025 and is based on reports of 17 SAEs worldwide (including two deaths) in ...

The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...

Now, in a recently released study of 117 children who were hospitalized between June and September 2024 (during the monsoon) ...

Copenhagen, Denmark Saturday, May 3, 2025, 12:00 Hrs [IST] ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the ...

VIMKUNYA is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization for the prevention ...

The Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Vimkunya, a vaccine used to prevent disease caused by the chikungunya virus in people 12 years of age and older. The ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Stay informed on the latest scams with a free biweekly newsletter ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (1 May 2025) approved a vaccine (Vimkunya) used to ...

Shares of French speciality vaccines developer Valneva (Nasdaq: VAL) were down 8.4% at 2.89 euros by early afternoon, after ...